Abstract: ［1］ Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016［J］. CA Cancer J Clin, 2016, 66(1): 730. DOI: 10.3322/caac.21332. ［2］  Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015［J］. CA Cancer J Clin, 2016, 66(2): 115132. DOI: 10.3322/caac.21338. ［3］  Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part Ⅱ: treatment of advanced, relapsing, and castrationresistant prostate cancer［J］. Eur Urol, 2014, 65(2): 467479. DOI: 10.1016/j.eururo.2013.11.002. ［4］ Cornford P, Bellmunt J, Bolla M, et al. EAUESTROSIOG guidelines on prostate cancer. Part Ⅱ: treatment of relapsing, metastatic, and castrationresistant prostate cancer［J］. Eur Urol, 2017, 71(4): 630642. DOI: 10.1016/j.eururo.2016.08.002. ［5］ Ceder Y, Bjartell A, Culig Z, et al. The molecular evolution of castrationresistant prostate cancer［J］. Eur Urol Focus, 2016, 2(5): 506513. DOI: 10.1016/j.euf.2016.11.012. ［6］ Chandrasekar T, Yang JC, Gao AC, et al. Mechanisms of resistance in castrationresistant prostate cancer (CRPC)［J］. Transl Androl Urol, 2015, 4(3): 365380. DOI: 10.3978/j.issn.22234683.2015.05.02. ［7］ Yamamoto Y, Loriot Y, Beraldi E, et al. Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamideresistant prostate cancer cell growth［J］. Clin Cancer Res, 2015, 21(7): 16751687. DOI: 10.1158/10780432.CCR141108. ［8］ Mostaghel EA, Marck BT, Plymate SR, et al. Resistance to CYP17A1 inhibition with abiraterone in castrationresistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants［J］. Clin Cancer Res, 2011, 17(18): 59135925. DOI: 10.1158/10780432.CCR110728. ［9］ Romanel A, Gasi Tandefelt D, Conteduca V, et al. Plasma AR and abirateroneresistant prostate cancer［J］. Sci Transl Med, 2015, 7(312): 312re10. DOI: 10.1126/scitranslmed.aac9511. ［10］  Boudadi K, Antonarakis ES. Resistance to novel antiandrogen therapies in metastatic castrationresistant prostate cancer［J］. Clin Med Insights Oncol, 2016, 10(Suppl1): 19. DOI: 10.4137/CMO.S34534. ［11］ Korpal M, Korn JM, Gao X, et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide)［J］. Cancer Discov, 2013, 3(9): 10301043. DOI: 10.1158/21598290.CD130142. ［12］ Kong D, Sethi S, Li Y, et al. Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes［J］. Prostate, 2015, 75(2): 161174. DOI: 10.1002/pros.22901. ［13］ Jin R, Yamashita H, Yu X, et al. Inhibition of NFkappa B signaling restores responsiveness of castrateresistant prostate cancer cells to antiandrogen treatment by decreasing androgen receptor variants expression［J］. Oncogene, 2015, 34(28): 37003710. DOI: 10.1038/onc.2014.302. ［14］ Deng C, Chen J, Guo S, et al. CX4945 suppresses the growth of castrationresistant prostate cancer cells by reducing ARV7 expression［J］. World J Urol, 2017, 35(8): 12131221. DOI: 10.1007/s003450161996y. ［15］ Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapynaive men with metastatic castrationresistant prostate cancer (COUAA302): final overall survival analysis of a randomised, doubleblind, placebocontrolled phase 3 study［J］. Lancet Oncol, 2015, 16(2): 152160. DOI: 10.1016/S14702045(14)712057. ［16］ Shi XB, Xue L, Ma AH, et al. Tumor suppressive miR124 targets androgen receptor and inhibits proliferation of prostate cancer cells［J］. Oncogene, 2013, 32(35): 41304138. DOI: 10.1038/onc.2012.425. ［17］ Wan X, Huang W, Yang S, et al. Androgeninduced miR27A acted as a tumor suppressor by targeting MAP2K4 and mediated prostate cancer progression［J］. Int J Biochem Cell Biol, 2016, 79: 249260. DOI: 10.1016/j.biocel.2016.08.043. ［18］ Wan X, Pu H, Huang W, et al. Androgeninduced miR135a acts as a tumor suppressor through downregulating RBAK and MMP11, and mediates resistance to androgen deprivation therapy［J］. Oncotarget, 2016, 7(32): 5128451300. DOI: 10.18632/oncotarget.9992. ［19］ Carver BS. Defining and targeting the oncogenic drivers of neuroendocrine prostate cancer［J］. Cancer Cell, 2016, 29(4): 431432. DOI: 10.1016/j.ccell.2016.03.023. ［20］ Tan HL, Sood A, Rahimi HA, et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma［J］. Clin Cancer Res, 2014, 20(4): 890903. DOI: 10.1158/10780432.CCR131982. ［21］ Ku SY, Rosario S, Wang Y, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance［J］. Science, 2017, 355(6320): 7883. DOI: 10.1126/science.aah4199. ［22］ Mu P, Zhang Z, Benelli M, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53 and RB1deficient prostate cancer［J］. Science, 2017, 355(6320): 8488. DOI: 10.1126/science.aah4307. ［23］ Dang Q, Li L, Xie H, et al. Antiandrogen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells→androgen receptor (AR)→miRNA32 signals［J］. Mol Oncol, 2015, 9(7): 12411251. DOI: 10.1016/j.molonc.2015.02.010. ［24］ Shiota M, Yokomizo A, Takeuchi A, et al. Inhibition of protein kinase C/Twist1 signaling augments anticancer effects of androgen deprivation and enzalutamide in prostate cancer［J］. Clin Cancer Res, 2014, 20(4): 951961. DOI: 10.1158/10780432.CCR131809. ［25］ Shang Z, Cai Q, Zhang M, et al. A switch from CD44+ cell to EMT cell drives the metastasis of prostate cancer［J］. Oncotarget, 2015, 6(2): 12021216. DOI: 10.18632/oncotarget.2841. ［26］ Leong KG, Wang BE, Johnson L, et al. Generation of a prostate from a single adult stem cell［J］. Nature, 2008, 456(7223): 804808. DOI: 10.1038/nature07427. ［27］ Jain AK, Allton K, Iacovino M, et al. p53 regulates cell cycle and microRNAs to promote differentiation of human embryonic stem cells［J］. PLoS Biol, 2012, 10(2): e1001268. DOI: 10.1371/journal.pbio.1001268. ［28］ Li L, Dang Q, Xie H, et al. Infiltrating mast cells enhance prostate cancer invasion via altering LncRNAHOTAIR/PRC2androgen receptor (AR)MMP9 signals and increased stem/progenitor cell population［J］. Oncotarget, 2015, 6(16): 1417914190. DOI: 10.18632/oncotarget.3651. ［29］ Akamatsu, Wyatt AW, Lin D, et al. The placental gene PEG10 promotes progression of neuroendocrine prostate cancer［J］. Cell Rep, 2015, 12(6): 922936. DOI: 10.1016/j.celrep.2015.07.012.

Key words: Prostatic neoplasms, Receptors, androgen, Carcinoma, neuroendocrine, Neoplastic stem cells, Transformation